Clinical trials in Heilbronn

987 clinical trials in Heilbronn, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Heilbronn at a glance

987

clinical trials

Research sites1

Quick filters

987 trials in Heilbronn

Open in trial search

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Chronic kidney disease

Recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Balcinrenone
Sponsor:AstraZeneca AB

Contact Research Centre

Mite allergy+1

Recruiting

Safety of a rush up‑dosing regimen of dust mite allergen extract versus conventional up‑dosing in adults with dust mite rhinitis/rhinoconjunctivitis with asthma

Registered drugNo placebo

Safety of a rush up‑dosing regimen of dust mite allergen extract versus conventional up‑dosing in adults with dust mite rhinitis/rhinoconjunctivitis with asthma

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Phenol
Sponsor:HAL Allergy B.V.

Contact Research Centre

Dermatitis atopic

Recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atebimetinib
Sponsor:Immuneering Corp.

Contact Research Centre

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Germany

Participants:18–64 years
Substances:Zenagamtide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Craniocerebral injury

Recruiting

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cenegermin
Sponsor:Dompe' Farmaceutici S.p.A.

Contact Research Centre

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Epinephrine
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heilbronn

What the registry says about research in the country

01 Blood Cancers

Innovative trials focusing on Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia, testing novel drug combinations to improve patient outcomes. Research includes evaluating treatments for both adult and pediatric patients with various forms of leukemia.

Novel drug combinations for AML treatment
Targeted therapies for specific genetic mutations
Pediatric leukemia protocols

Studies aim to enhance survival rates and develop more effective treatment strategies for blood cancer patients.

02 Breast Cancer Research

Comprehensive studies addressing different types of breast cancer, particularly focusing on triple-negative breast cancer and HER2-positive disease. Research includes both early-stage and metastatic disease treatments.

Advanced therapeutic approaches for TNBC
Adjuvant therapy optimization
Personalized treatment strategies

Trials evaluate novel drug combinations and targeted therapies to improve patient outcomes.

03 Gastrointestinal Oncology

Research focusing on various digestive system cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Studies evaluate both early-stage and advanced disease treatments.

Advanced gastric cancer therapies
Preoperative treatment strategies
Novel combination approaches

Investigations aim to improve surgical outcomes and treatment effectiveness for GI cancers.

Back to Germany All countries